Oncological features and prognosis of colorectal cancer in human immunodeficiency virus-positive patients: A retrospective study

doi:10.4240/wjgs.v16.i1.29

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1851)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

WORD

HTML

669

Figures (1-2)

155

Tables (1-6)

196

Sum=1078

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

115

Download

255

Sum=370

Publishing Process of This Article

Item

Count

Browse

Download

257

Sum=350

Jan 27, 2024 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Surg. Jan 27, 2024; 16(1): 29-39
Published online Jan 27, 2024. doi: 10.4240/wjgs.v16.i1.29

Table 1 Comparison of baseline data before and after propensity score matching

	Before PSM			After PSM
	HIV-negative (n = 363)	HIV-positive (n = 24)	P value	HIV-negative (n = 48)	HIV-positive (n = 24)	P value
Sex			1			1
Male	211 (58.1)	14 (58.3)		29 (60.4)	14 (58.3)
Female	152 (41.9)	10 (41.7)		19 (39.6)	10 (41.7)
Age (yr)	66.3 ± 10.6	63.6 ± 12.0	0.283	64.3 ± 12.4	63.6 ± 12.0	0.808
Tumor			0.466			0.833
Proximal colon	126 (34.7)	7 (29.2)		11 (22.9)	7 (29.2)
Distal colon	101 (27.8)	5 (20.8)		10 (20.8)	5 (20.8)
Rectum	136 (37.5)	12 (50.0)		27 (56.2)	12 (50.0)
Degree of differentiation			0.572			1
Low	36 (9.9)	3 (12.5)		6 (12.5)	3 (12.5)
Moderate	316 (87.1)	20 (83.3)		40 (83.3)	20 (83.3)
High	11 (3.0)	1 (4.2)		2 (4.2)	1 (4.2)
Tumor stage			0.425			1
T1	18 (5.0)	0 (0.0)		0 (0.0)	0 (0.0)
T2	53 (14.6)	6 (25.0)		13 (27.1)	6 (25.0)
T3	200 (55.1)	13 (54.2)		25 (52.1)	13 (54.2)
T4a	73 (20.1)	3 (12.5)		7 (14.6)	3 (12.5)
T4b	19 (5.2)	2 (8.3)		3 (6.2)	2 (8.3)

¹The tumor sites of colorectal cancer were classified as proximal colon (ICD-O3C180-84), distal colon (ICD-O3C185-87), and rectum (ICD-O3C199, C209) according to the International Classification of Diseases in Oncology.

Variables are expressed as median (P25, P75) or n (%). PSM: Propensity score matching; HIV: Human immunodeficiency virus; T: Tumor.

Table 2 Patient baseline data of the two groups

	HIV-positive (n = 24)	HIV-negative (n = 48)	P value
CRC family history	1 (4.2)	5 (10.4)	0.656
Main comorbidity	8 (33.3)	18 (37.5)	0.729
Hypertension	4 (16.7)	11 (22.9)	0.538
Diabetes mellitus	2 (8.3)	8 (16.7)	0.479
CHD	4 (16.7)	5 (10.4)	0.469
COPD	0	2 (4.2)	0.549
Drinking	6 (25)	16 (33.3)	0.469
Smoking	4 (16.7)	11 (22.9)	0.538
Abdominal surgery history	5 (20.8)	8 (16.7)	0.749
BMI (kg/m²)	22.06 (19.71, 23.95)	23.02 (21.03, 25.17)	0.074
Chemotherapy	7 (29.2)	30 (62.5)	0.008
Adverse reactions of chemotherapy	2 (28.6)	15 (50)	0.416
Fever¹	0	0	NA

¹Recurrent fever before or after surgery.

Variables are expressed as median (P25, P75) or n (%). HIV: Human immunodeficiency virus; CRC: Colorectal cancer; CHD: Coronary atherosclerotic heart disease; COPD, Chronic obstructive pulmonary disease; BMI: Body mass index; NA: Not available.

Table 3 Comparison of perioperative serologic indicators between human immunodeficiency virus-positive and -negative patients

	HIV-positive (n = 24)	HIV-negative (n = 48)	P value
Preoperative leukocytes (10⁹)	5.36 (3.85, 6.70)	5.92 (4.95, 7.50)	0.049
Postoperative leukocytes (10⁹)	6.91 (5.36, 8.84)	8.98 (6.97, 10.89	0.013
Preoperative hemoglobin (g/L)	123.50 (101.25, 139.75)	128.00 (120.00, 140.00)	0.229
Postoperative hemoglobin (g/L)	121.50 (96.00, 127.00)	119.00 (107.25, 125.25)	0.976
Preoperative lymphocytes (10⁹)	1.19 (0.77, 1.48)	1.48 (1.18, 1.90)	0.028
Postoperative lymphocyte	0.75 (0.49, 0.98)	0.79 (0.61, 1.07)	0.685
Preoperative albumin (g/L)	43.00 (37.00, 45.00)	41.00 (38.00, 44.00)	0.807
Postoperative albumin (g/L)	32.00 (28.00, 36.00)	29.00 (25.00, 34.75)	0.087
CEA (μg/L)	2.27 (1.38, 3.10)	5.44 (2.90, 20.00)	0.012
CA19-9 (U/mL)	13.96 (5.40, 20.85)	15.00 (6.99, 34.68)	0.983

Variables are expressed as median (P25, P75) or n (%). HIV: Human immunodeficiency virus; CEA: Carcinoembryonic Antigen; CA19-9: Carbohydrate antigen 199.

Table 4 Comparison of surgical outcomes between the two groups

	HIV-positive (n = 24)	HIV-negative (n = 48)	P value
Intraoperative blood loss (mL)	100 (50, 100)	50 (34, 100)	0.046
Operation time (min)	187.50 (151.25, 227.25)	195.00 (144.75, 240.00)	0.77
Time to first flatus (d)	3 (2, 4)	3 (2.25, 6)	0.668
Time to first defecation (d)	3 (1.25, 4.75)	3 (2, 6)	0.257
Time to first liquid intake (d)	2.5 (2, 3)	3 (2.25, 4)	0.064
Time to ambulation (d)	3 (3, 6.25)	3.5 (3, 4)	0.98
Postoperative hospital stay (d)	9 (7, 13.25)	8 (7, 11)	0.655
Postoperative complications	3 (12.5)	5 (10.4)	1.000
Admission to ICU	1 (4.2)	9 (18.8)	0.149
Time to stopping antibiotics (days)	2 (1, 2.75)	2 (1, 3.75)	0.679
Hospitalization expenses (thousand yuan)	78.7 (65.3, 88.6)	81.4 (67.5, 134.1)	0.173
PS at 1 mo after operation	1 (1, 1)	1 (1, 1)	0.48
Long-term postoperative gastrointestinal discomfort	8 (33.3)	12 (25)	0.457
Decrease in hemoglobin (g/L)	11 (0.5, 18.75)	12 (4, 22)	0.385
Decrease in albumin (g/L)	9.28 (4.75, 13.28)	12 (7, 15)	0.071
Intraoperative blood transfusion	1 (4.2)	1 (2.1)	1.000
Enterostomy	7 (29.2)	10 (20.8)	0.433
Readmission within 1 mo	0	0	NA
Death within 1 mo	0	0	NA
ASA score	3 (2, 3)	2 (2, 3)	0.713

Variables are expressed as median (P25, P75) or n (%). HIV: Human immunodeficiency virus; ICU: Intensive care unit; PS: Performance status; ASA: American Society of Anesthesiologists; NA: Not available.

Table 5 Oncological characteristics of patients in the two groups

	HIV-positive (n = 24)	HIV-negative (n = 48)	P value
Number of metastatic lymph nodes	1 (0, 3.5)	0 (0, 0)	0.001
Node stage	1 (0, 1.75)	0 (0, 1)	0.005
Harvested lymph nodes	13 (10, 15.75)	14.5 (11.25, 18)	0.223
Size of largest lymph node	0.85 (0.525, 1.45)	0.8 (0.5, 1)	0.318
Metastasis	2 (8.3)	2 (4.2)	0.597
TNM stage	3 (2, 3)	2 (2, 2.75)	0.004
Tumor size (cm)	3.75 (2.5, 5)	4 (3, 5)	0.497
Margin	0	0	NA
MSI	1 (11.1)	1 (6.3)	1
RAS gene mutation	3 (37.5)	13 (76.5)	0.087
BRAF gene mutation	0	1 (5.8)	1
MLH1	14 (82.4)	35 (92.1)	0.359
MSH2	16 (94.1)	37 (97.4)	0.527
MSH6	16 (94.1)	37 (97.4)	0.527
Ki-67 (%)	70 (60, 80)	60 (50, 80)	0.159

Variables are expressed as median (P25, P75) or n (%). HIV: Human immunodeficiency virus; MSI: Microsatellite instability; TNM: Tumor-Node-Metastasis; RAS: Rat sarcoma; BRAF: Serine/threonine protein kinase B-raf; MLH1: MutL homologue 1; MSH: Melanocyte-stimulating hormone; Ki-67: Antigen identified by monoclonal antibody Ki-67; NA: Not available.

Table 6 The number of metastatic lymph nodes, node stage, and tumor node metastasis stage in patients at different tumor stages

	T2 (n = 19)	T3 (n = 38)	T4a (n = 10)	T4b (n = 5)
Number of metastatic lymph nodes
HIV-positive	1 (0, 1.25)	1 (0, 3.5)	0 (0, -)	6 (4, -)
HIV-negative	0 (0, 0)	0 (0, 0)	0 (0, 3)	1 (0, -)
Node stage (0/I/II)
HIV-positive	2/4/0	5/5/3	2/0/1	0/0/2
HIV-negative	10/3/0/0	18/4/3	5/1/1	1/2/0
TNM stage (I/II/III/IV)
HIV-positive	2/0/4/0	0/5/8/0	0/2/1/0	0/0/0/2
HIV-negative	11/0/2/0	0/20/4/1	0/5/2/0	0/0/2/1

Variables are expressed as median (P25, P75) or n. HIV: Human immunodeficiency virus; T: Tumor; TNM: Tumor-Node-Metastasis.

Citation: Yang FY, He F, Chen DF, Tang CL, Woraikat S, Li Y, Qian K. Oncological features and prognosis of colorectal cancer in human immunodeficiency virus-positive patients: A retrospective study. World J Gastrointest Surg 2024; 16(1): 29-39
URL: https://www.wjgnet.com/1948-9366/full/v16/i1/29.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i1.29